Evotec SE and Novo Nordisk Launch LAB eN² Projects for Drug Discovery

Evotec SE and Novo Nordisk have announced the first projects for their LAB eN² drug discovery accelerator, focusing on cardiometabolic diseases. Three projects from Boston University, Harvard University, and Joslin Diabetes Center have been selected. LAB eN² is expanding to include five new academic institutions, enhancing its collaborative network.

Dr. Thomas Hanke from Evotec highlighted the accelerator's role in translating research into therapies. Boston University's project targets chronic kidney disease and obesity. Harvard's study explores metabolic disease pathways, while Joslin Diabetes Center focuses on type 1 diabetes with an innovative immune response approach.

Initial projects receive a Discovery Award for pre-clinical development, with potential for further funding. Novo Nordisk's Uli Stilz emphasized the accelerator's success in bridging research gaps. Launched in 2023, LAB eN² continues to grow, fostering scientific advancements with academic partnerships.